**Abstract**

**Background**: Epigenetic modification including DNA methylation may have effects on response to antipsychotics in schizophrenia. The Taq1A is located 10kb downstream of *DRD2*, and causes an amino substitution within the 11th ankyrin repeat of ankyrin repeat and kinase domain containing 1 (ANKK1). We investigated the effects of the DNA methylation of Taq1A in *DRD2* on the response to aripiprazole and plasma levels of homovanillic acid (HVA) and 3-methoxy-4hydroxyphenylglycol (MHPG) in antipsychotic-free acute schizophrenic patients.

**Methods**: Subjects were 34 Japanese patients with schizophrenia, and were treated with aripiprazole for 6 weeks. The Positive and Negative Syndrome Scale (PANSS) was used for assessment of clinical symptoms. Plasma levels of HVA and MHPG were measured using high-performance liquid chromatography before and after the treatment. The DNA methylation levels of all CpG sites ranging from -162 C to +260 C of 5' region of ANKK1 gene were determined by sequencing using next-generation sequencer. This study was approved by the ethics committee of Fukushima Medical University, and the patients consented to participate after having been informed of the purpose of the study.

**Results**: Aripiprazole decreased PANSS scores after the 6 weeks. Plasma levels of HVA (p=0.01) and MHPG (p=0.002) decreased in responders after the 6 weeks treatment, but not in non-responders. In responders, DNA methylation of Taq1A was significantly higher than non-responders at 3 CpG sites. Furthermore, methylation levels of Taq1A were correlated with changes in plasma levels of HVA and MHPG in 4 and 3 CpG sites, respectively.

**Conclusion**: This is the first study of the association between the DNA methylation of Taq1A in *DRD2* and the response to aripiprazole, suggesting that methylation of Taq1A at specific sites may have effects on the response to antipsychotics. Because of the small sample size, further studies are needed to confirm these results.
